Randomized Phase 3 Study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma. An AMN Study
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms An AMN Study
- 09 May 2019 Planned End Date changed from 1 Jun 2022 to 31 Mar 2020.
- 09 May 2019 Status changed from recruiting to active, no longer recruiting.
- 01 Nov 2017 Status changed from not yet recruiting to recruiting.